Human monocytoid leukemia cells are highly sensitive to apoptosis induced by 2'-deoxycoformycin and 2'-deoxyadenosine: Association with dATP- dependent activation of caspase-3

Blood

Volumn 92, Issue 9, 1998, Pages 3368-3375

  Niitsu, Nozomi ^b   Yamaguchi, Yuri ^b   Umeda, Masanori ^b   Honma, Yoshio ^a  

^a SAITAMA CANCER CENTER   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE INHIBITOR; DEOXYADENOSINE; PENTOSTATIN;

ACUTE MONOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0032212320     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.9.3368     Document Type: Article

References (44)

1. Fenaux P, Vanhaesbroucke C, Estienne MH, Homme CP, Pagniez D, Facon T, Millot F, Bauters F: Acute monocytic leukaemia in adults: Treatment and prognosis in 99 cases. Br J Haematol 75:41, 1990
2. Kodama K, Kusakabe H, Machida H, Midorikawa Y, Shibuya S, Kuninaka A, Yoshino H: Isolation of 2′-deoxycoformycin and cordycepin from wheat bran culture of Aspergillus nidulaus Y-176-2. Agric Biol Chem 43:2375, 1979
3. Kraut EH, Bouroncle BA, Grever MR: Low-dose deoxycoformycin in the treatment of hairy cell leukemia. Blood 68:1119, 1986
4. Yamaguchi K, Yul LS, Oda T, Maeda Y, Ishii M, Fujita K, Kagiyama S, Nagai K, Suzuki H, Takatsuki K: Clinical consequences of 2′-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia. Leuk Res 10:989, 1986
5. Grever MR, Bisaccia E, Sarborough DA, Metz EN, Neidhart JA: An investigation of 2′-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 61:279, 1983
6. Murphy SB, Sinkule JA, Rivera G: Phase I-II clinical and pharmacodynamic study of effects of 2′-deoxycoformycin administered by continuous infusion in children with refractory acute lymphoblastic leukemia. Cancer Treat Symp 2:55, 1984
7. Dearden C, Catovsky D: Deoxycoformycin in the treatment of mature B-cell malignancies. Br J Cancer 62:4, 1990
8. Russell NH, Prentics HG, Lee N, Piga A, Ganeshaguru K, Smyth JF, Hoffbrand AV: Studies on the biochemical sequelae of therapy in Thy-acute lymphoblastic leukemia with the adenosine deaminase inhibitor 2′-deoxycoformycin. Br J Haematol 49:1, 1981
9. Kefford RF, Fox RM: Deoxycoformycin-induced response in chronic lymphocytic leukemia: Deoxyadenosine toxicity in non-replicating lymphocytes. Br J Haematol 50:627, 1982
10. Seto S, Carrera CJ, Kubota M, Wasson D, Carson DA: Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to non-dividing human lymphocytes. J Clin Invest 75:377, 1985
11. Niitsu N, Umeda M, Honma Y: Induction of differentiation of human myeloid leukemia cells by 2′-deoxycoformycin in combination with 2′-deoxyadenosine. Biochem Biophys Res Commun 238:100, 1997
12. Kanatani Y, Kasukabe T, Okabe-Kado J, Hayashi S, Yamamoto-Yamaguchi Y, Motoyoshi K, Nagata N, Honma Y: Transforming growth factor β and dexamethasone cooperatively enhance c-jun gene expression and inhibit the growth of human monocytoid leukemia cells. Cell Growth Diff 7:187, 1996
13. Kanatani Y, Kasukabe T, Hozumi M, Motoyoshi K, Nagata N, Honma Y: Genistein exhibits preferential cytotoxicity to a leukemogenic variant but induces differentiation of a non-leukemogenic variant of the mouse monocytic leukemia Mm cell line. Leuk Res 17:847, 1993
14. Camici M, Turriani M, Tozzi MG, Turchi G, Cos J, Alemany C, Miralles A, Noe V, Ciudad C: Purine enzyme profile in human colon-carcinoma cell lines and differential sensitivity to deoxycoformycin and 2′-deoxyadenosine in combination. Int J Cancer 62:176, 1995
15. Honma Y, Onozuka Y, Okabe-Kado J, Kasukabe T, Hozumi M: Hemin enhances the sensitivity of erythroleukemia cells to 1-β-D-arabinofuranosylcytosine by both activation of deoxycytidine kinase and reduction of cytidine deaminase activity. Cancer Res 51:4535, 1991
16. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, Elliston KO, Ayala JM, Casano FJ, Chin J, Ding GJ-F, Egger LA, Gaggney EP, Limjuco G, Palyha OC, Raju SM, Rolando AM, Schmidt JA, Tocci MJ: A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 356:768, 1992
17. Kobayashi Y, Ichijo Y, Nagatake H, Watanabe N, Nishizawa K, Goto M: Processing of interleukin-1β in synovial cells freshly isolated from patients with rheumatoid arthritis. Biochem Biophys Res Commun 199:1035, 1994
18. Liu X, Kim CN, Yang J, Jemmerson R, Wang X: Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c. Cell 86:147, 1996
19. Li F, Srinivasan A, Wang Y, Armstrong RC, Tomaselli KJ: Cell-specific induction of apoptosis by microinjection of cytochrome c. J Biol Chem 272:30299, 1997
20. Lee N, Russell N, Ganeshaguru K, Jackson BFA, Piga A, Prentice HG, Foa R, Hoffbrand V: Mechanisms of deoxyadenosine toxicity in human lymphoid cells in vitro: Relevance to the therapeutic use of inhibitors of adenosine deaminase. Br J Haematol 56:107, 1984
21. Kredich NM, Martin DW Jr: Role of S-adenosylhomocysteine in adenosine-mediated toxicity in cultured mouse lymphoma cells. Cell 12:931, 1977
22. Niitsu N, Yamamoto-Yamaguchi Y, Kanatani Y, Shuto S, Matsuda A, Umeda M, Honma Y, Neplanocin A, a potent inhibitor of S-adenosylhomocysteine hydrolase, potentiates granulocytic differentiation of acute promyelocytic leukemia cells induced by all-trans retinoic acid. Exp Hematol 25:1296, 1997
23. Arner E, Spasokoutskaja T, Juliusson G, Liliemark J, Eriksson S: Phosphorylation of 2-chlorodeoxyadenosine (CdA) in extracts of peripheral blood mononuclear cells of leukemic patients. Br J Haematol 87:715, 1994
24. Brockman RW, Cheng Y-C, Schabel FM, Montgomery JA: Metabolism and chemotherapeutic activity of 9-β-D-arabinofuranosyl- 2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res 40:3610, 1980
25. Enari M, Hug M, Nagata S. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 375:78, 1995
26. Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homologue to Caenorhabditis elegans cell death protein ced-3 and mammalian interleukin-1β-converting enzyme. J Biol Chem 269:30761, 1994
27. Nicholson WD, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, Smulsom ME, Yamin TT, Yu VL, Miller DK: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37, 1995
28. Gonzales DH, Neupert W. Biogenesis of mitochondrial c-type cytochromes. J Bioenerg Biomembr 22:753, 1990
29. Sylwestrowicz T, Piga A, Murphy P, Ganeshaguru K, Russell NH, Prentice HG, Hoffbrand AV: The effects of deoxycoformycin and deoxyadenosine on deoxyribonucleotide concentrations in leukaemia. Br J Haematol 51:623, 1982
30. Adams A, Harkness RA: Adenosine deaminase activity in thymus and other human tissues. Clin Exp Immunol 26:647, 1976
31. Ganeshaguru K, Lee N, Llewellin P, Prentice HG, Hoffbrand AV, Catovsky D, Habeshaw JA, Robinson J, Greaves MF: Adenosine deaminase concentrations in leukemia and lymphoma: Relation to cell phenotypes. Leuk Res 5:215, 1981
32. Smyth JF, Harrap KR: Adenosine deaminase activity in leukemia. Br J Cancer 31:544, 1975
33. Daddona P: Human adenosine-deaminase properties and turnover in cultured T and B lymphoblast. J Biol Chem 256:12496, 1981
34. O'Dwyer PJ, Wagner B, Leyland-Jones B, Wittes RE, Cheson BD, Hoth DF: 2′-Deoxycoformycin (Pentostatin) for lymphoid malignancies: Rational development of an active new drug. Ann Intern Med 108:733, 1988
35. Mashima T, Naito M, Kataoka S, Kawai H, Tsuruo T: Aspartate-based inhibitor of interleukin 1β-converting enzyme prevents antitumor agent-induced apoptosis in human myeloid leukemia U937 cells. Biochem Biophys Res Commun 209:907, 1995
36. Del Bino G, Bruno S, Yi PN, Darzynkiewicz Z: Apoptotic cell death triggered by camptothecin or teniposide. The cell cycle specificity and effects of ionizing radiation. Cell Prolif 25:537, 1992
37. Gunji H, Kharbanda S, Kufe D: Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1β-D- arabinofuranosylcytosine. Cancer Res 51:741, 1991
38. Schlegel J, Peters I, Orrenius S, Miller DK, Thornberry NA, Yamin TT, Nicholson DW: CPP32/Apopain is a key interleukin 1β converting enzyme-like protease involved in Fas-mediated apoptosis. J Biol Chem 271:1841, 1996
39. Wang X, Zeienski NG, Yang J, Sakai J, Brown MS, Goldstein JL: Cleavage of sterol regulatory element binding proteins (SREBPs) by CPP32 during apoptosis. EMBO J 15:1012, 1996
40. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazabnik YA, Munday NA, Raju SM, Smulsom ME, Yamin TT, Yu VL, Miller DK: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37, 1995
41. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmadt M, Alnemri ES, Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479, 1997
42. Martins LM, Mesner PW, Kottke TJ, Basai GS, Sinha S, Tung JS, Svingen PA, Madden BJ, Takahashi A, McCormick DJ, Earnshaw WC, Kaufmann SH: Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood 90:4283, 1997
43. Williams GT, Smith CA. Molecular regulation of apoptosis: Genetic controls on cell death. Cell 74:777, 1993
44. Oltvai ZN, Milliman CL, Korsmeyer SJ: Checkpoints of dueling dimers foil death wishes. Cell 79:189, 1994